Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Antibe Therapeutics Inc (ATE.TO)

Antibe Therapeutics Inc (ATE.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 34,590
  • Shares Outstanding, K 51,627
  • Annual Sales, $ 9,713 K
  • Annual Income, $ -26,301 K
  • 60-Month Beta -0.12
  • Price/Sales 2.46
  • Price/Cash Flow N/A
  • Price/Book 0.48
Trade ATE.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.67
  • Most Recent Earnings -0.13 on N/A
  • Next Earnings Date 11/18/21
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.15
  • Number of Estimates 4
  • High Estimate -0.07
  • Low Estimate -0.25
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.66 +6.06%
on 12/01/21
1.01 -30.69%
on 11/04/21
-0.25 (-26.32%)
since 11/02/21
3-Month
0.66 +6.06%
on 12/01/21
1.30 -46.15%
on 09/17/21
-0.51 (-42.15%)
since 09/02/21
52-Week
0.66 +6.06%
on 12/01/21
7.52 -90.69%
on 02/17/21
-3.25 (-82.28%)
since 12/02/20

Most Recent Stories

More News
Antibe Therapeutics Reports Q2 2022 Interim Financial and Operating Results

Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has filed its financial and...

ATE.TO : 0.70 (+4.48%)
ATBPF : 0.5379 (+2.46%)
Antibe Therapeutics Outlines Plan for Otenaproxesul's Acute Pain Program

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions,...

ATE.TO : 0.70 (+4.48%)
ATBPF : 0.5379 (+2.46%)
Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions,...

ATE.TO : 0.70 (+4.48%)
ATBPF : 0.5379 (+2.46%)
Antibe Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions,...

ATE.TO : 0.70 (+4.48%)
ATBPF : 0.5379 (+2.46%)
Antibe Therapeutics Announces Results of 2021 Annual Meeting

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to announce...

ATE.TO : 0.70 (+4.48%)
ATBPF : 0.5379 (+2.46%)
Antibe Therapeutics Reports Q1 2022 Interim Financial and Operating Results

Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has filed its financial and...

ATE.TO : 0.70 (+4.48%)
ATBPF : 0.5379 (+2.46%)
Antibe Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions,...

ATE.TO : 0.70 (+4.48%)
ATBPF : 0.5379 (+2.46%)
Antibe Therapeutics Provides Clinical Update for Otenaproxesul

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has placed its absorption,...

ATE.TO : 0.70 (+4.48%)
ATBPF : 0.5379 (+2.46%)
Antibe Therapeutics Provides July 2021 Corporate Update

Antibe Therapeutics Inc.:

ATE.TO : 0.70 (+4.48%)
Antibe Therapeutics Reports 2021 Year-End Financial Results and Business Highlights

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today filed its financial...

ATE.TO : 0.70 (+4.48%)
ATBPF : 0.5379 (+2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 0.73
2nd Resistance Point 0.72
1st Resistance Point 0.69
Last Price 0.70
1st Support Level 0.65
2nd Support Level 0.64
3rd Support Level 0.61

See More

52-Week High 7.52
Fibonacci 61.8% 4.90
Fibonacci 50% 4.09
Fibonacci 38.2% 3.28
Last Price 0.70
52-Week Low 0.66

See More

Business Summary

Antibe Therapeutics Inc develops and out-licenses new pharmaceuticals. Its main objective is to develop its lead compound otenaproxesul, by satisfying the requirements of the relevant drug regulatory authorities while also satisfying the commercial licensing objectives of prospective global partners....

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar